Protection against developmental retardation in apolipoprotein E- deficient mice by a fatty neuropeptide: Implications for early treatment of Alzheimer's disease

Journal of Neurobiology

Volumn 33, Issue 3, 1997, Pages 329-342

  Gozes, Illana ^a   Bachar, Michal ^a   Bardea, Amos ^a   Davidson, Ariane ^a   Rubinraut, Sarah ^b   Fridkin, Mati ^b   Giladi, Eli ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Apolipoprorein E; Cholinergic activity; Developmental milestones; Learning and memory; Messenger RNA; Vasoactive intestinal peptide

Indexed keywords

APOLIPOPROTEIN E; CHOLINE ACETYLTRANSFERASE; DIMETHYL SULFOXIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MESSENGER RNA; NEUROPEPTIDE; SODIUM CHLORIDE; STEARIC ACID DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CHOLINERGIC ACTIVITY; COGNITION; CONTROLLED STUDY; FORELIMB; GENOTYPE; GROWTH RETARDATION; HYPERLIPOPROTEINEMIA TYPE 3; LEARNING DISORDER; MOTOR ACTIVITY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; BRAIN; BRAIN DISEASES; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC FIBERS; LEARNING; MEMORY DISORDERS; MICE; MICE, KNOCKOUT; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; RNA, MESSENGER; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0030752973     PISSN: 00223034     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4695(199709)33:3<329::AID-NEU10>3.0.CO;2-A     Document Type: Article

References (76)

1. AGOSTON, D. V., EIDEN, L. E., BRENNEMAN, D. E., and GOZES, I. (1991). Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures. Mol. Brain Res. 10:235-240.
2. ALTMAN, J., and SUNDARSHAN, K. (1975). Postnatal development of locomotion in the laboratory rat. Anim. Behav. 23:896-920.
3. ARIMURA, A. (1992). Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul. Peptides 37:287-303.
4. ARIMURA, A., SOMOGYVARI-VIGH, A., WEILL, C., FIORE, R. C., TATSUNO, I., BAY, V., and BRENNEMAN, D. E. (1994). PACAP functions as a neurotrophic factor. Ann. NY Acad. Sci. 739:228-243.
5. BRENNEMAN, D. E., and EIDEN, L. E. (1986). Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. USA 83:1159-1162.
6. BRENNEMAN, D. E., EIDEN, L. E., and SIEGEL, R. E. (1985). Neuropeptide regulation of neuronal development in spinal cord cultures. Peptides 6:35-39.
7. BRENNEMAN, D. E., and GOZES, I. (1996). A femtomolaracting neuroprotective peptide. J. Clin. Invest. 97:2299-2307.
8. BRUMBACK, R. A., and LEECH, R. W. (1994). Alzheimer's disease: pathophysiology and hope for therapy. J. Okla. State Med. Assoc. 87:103-111.
9. CORDER, E. H., SAUNDERS, A. M., STRITTMATTER, W. J., SCHMECHEL, D. E., GASKELL, P. C., RIMMLER, J. B., Jr., LOCKE, P. A., CONNEALLY, P. M., SCHMADER, K. E., and TANZI, R. E. (1995). Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 45:1323-1328.
10. Cottrell, G. A., VELDHUIS, H. D., ROSTENE, W. H., and DE KLOET, E. R. (1984). Behavioral actions of vasoactive intestinal peptide (VIP). Neuropeptides 4:331-341.
11. DIERKS, T., IHL, R., FROLICH, L., and MAURER, K. (1993). Dementia of the Alzheimer's type: effects on the spontaneous EEG described by dipole sources. Psychiatry Res. 50:151-162.
12. FATATIS, A., HOLTZCLAW, L. A., AVIDOR, R., BRENNEMAN, D. E., and RUSSELL, J. T. (1994). VIP increases intracellular calcium in astroglia: synergism with alpha-adrenergic receptors. Proc. Natl. Acad. Sci. USA 91:2036-2040.
13. FONNUM, F. (1975). A rapid radiochemical method for the determination of cholinacetyl transferase. J. Neurochem. 24:407-409.
14. Fox, W. M. (1965). Reflex-ontogeny and behavioral development of the mouse. Anim. Behav. 13:234-241.
15. GENIS, I., GORDON, I., SEHAYEK, E., and MICHAELSON, D. M. (1995). Phosphorylation of tau in apolipoprotein E-deticient mice. Neurosci. Lett. 199:5-8.
16. GLAZER, R., and GOZES, I. (1994). Diurnal oscillation in vasoactive intestinal peptide gene expression independent of environmental light entraining. Brain Res. 644:164-168.
17. GLOWA, J. R., PANLILIO, L. V., BRENNEMAN, D. E., GOZES, I., FRIDKIN, M., and HILL, J. M. (1992). Learning impairment following intracerebral administration of the HIV envelope protein gp 120 or a VIP antagonist. Brain Res. 570:49-53.
18. GORDON, I., GRAUER, E., GENIS, I., SEHAYEK, E., and MICHAELSON, D. M. (1995). Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci. Lett. 199:1-4.
19. GOZES, I., BARDEA, A., RESHEF, A., ZAMOSTIATNO, R., ZHUKOVSKY, S., RUBINRAUT, S., FRIDKIN, M., and BRENNEMAN, D.E. (1996). Novel neuroprotective strategy for Alzheimer's disease: inhalation of a fatty neuropeptide. Proc. Natl. Acad. Sci. USA 93:427-432.
20. GOZES, I., and BRENNEMAN, D. E. (1993). Neuropeptides as growth and differentiation factors in general and VIP in particular. J. Mol. Neurosci. 4:1-9.
21. GOZES, I., FRIDKJN, M., and BRENNEMAN, D. E. (1995b). Stearyl-Nle-VIP: a non-invasive impotence drug and a potent agent of neuro-protection. Drugs Future 20:680-685.
22. GOZES, I., FRIDKIN, M., and BRENNEMAN, D. E. (1995c). A VIP hybrid antagonist: from neurotrophism to clinical applications. Cell. Mol. Neurobiol. 15:675-687.
23. GOZES, I., GLOWA, J. M., BRENNEMAN, D. E., MCCUNE, S. K., LEE, E., and WESTPHAL, H. (1993). Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J. Mol. Neurosci. 4:185-193.
24. GOZES, I., LILLING, G., GLAZER, R., TICHER, A., ASHKENAZI, I. E., DAVIDSON, A., RUBINRAUT, S., FRIDKIN, M., and BRENNEMAN, D. E. (1995a). Superactive lipophilic peptides discriminate multiple VIP receptors. J. Pharmacol. Exp. Ther. 273:161-167.
25. GOZES, I., MELTZER, E., RUBINRAUT, S., BRENNEMAN, D. E., and FRIDKIN, M. (1989). Vasoactive intestinal peptide potentiate sexual behavior: inhibition by novel antagonist. Endocrinology 125:2945-2949.
26. GOZES, I., NAKAI, H., BYERS, M., AVIDOR, R., WEINSTEIN, Y., SHANI, Y., and SHOWS, T. B. (1987b). Sequential expression in the nervous system of the VIP and c-myb genes located on the human chromosomal region 6q24. Somat. Cell Mol. Gen. 13:305-313.
27. GOZES, I., RESHEF, A., SALAH, D., RUBINRAUT, S., and FRIDKIN, M. (1994). Stearyl-norleucine-VIP, a novel VIP analogue for noninvasive impotence treatment. Endocrinology 134:2121-2125.
28. GOZES, I., SHACHTER, P., SHANI, Y., and GILADI, E. (1988). Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology 47:27-31.
29. GOZES, I., SHANI, Y., and ROSTENE, W. H. (1987a). Developmental expression of the VIP-gene in brain and intestine. Mol. Brain Res. 2:137-148.
30. GRESSENS, P., HILL, J. M., PAINDAVEINE, B., GOZES, I., FRIDKIN, M., and BRENNEMAN, D. E. (1994). Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94:2020-2027.
31. HILL, J. M., GOZES, I., HILL, J. L., FRIDKIN, M., and BRENNEMAN, D. E. (1991). Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides 12:187-192.
32. HILL, J. M., MERVIS, R. F., POLITI, J., MCCUNE, S. K., GOZES, I., FRIDKIN, M., and BRENNEMAN, D.E. (1994). Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann. NY Acad. Sci. 739:211-225.
33. HOHMANN, C. F., and EBNER, F. F. (1985). Development of cholinergic markers in mouse forebrain. I. Choline acetyltransferase activity and acetylcholinetransferase histochemistry. Brain Res. 355:225-241.
34. HOLLER, T., BERSE, B., CERMAK, J. M., DIEBLER, M.-F., and BLUSZTAJN, J. K. (1996). Differences in the developmental expression of the vesicular acetylcholine transporter and choline acetyltransferase in the rat brain. Neurosci. Lett. 212:107-110.
35. HYMAN, B. T., WEST, H. L., REBECK, G. W., LAI, F., and MANN, D.M. (1995). Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch. Neurol. 52:373-378.
36. KAISER, P. K., and LIPTON, S. A. (1990). VIP-mediated increase in cAMP prevents etrodotoxin-induced retinal ganglion cell death in vitro. Neuron 5:373-381.
37. KOVACS, D. M., WASCO, W., WITHERBY, J., FELSENSTEIN, K. M., BRUNEL, F., ROEDER, R. G., and TANZI, R. E. (1995). The upstream stimulatory factor functionally interacts with the Alzheimer's beta amyloid precursor gene. Hum. Mol. Genet. 4:1527-1533.
38. KOWALL, N. W., BEAL, M. F., BUSCIGILIO, J., DUFFY, L. K., and YANKNBR, B. A. (1991). An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc. Natl. Acad. Sci. USA 88:7247-7251.
39. LEVY-HOLTZMAN, R., MALACH, R., and GOZES, I. (1989). Disruption of the optic pathway during development affects vasoactive intestinal peptide mRNA expression. New Biol. 1:215-221.
40. LEVY-LAHAD, E., WIJSMAN, E. M., NEMENS, E., ANDERSON, L., GODDARD, K. A. B., WEBER, J. L., BIRD, T. D., and SCHELLENBERG, G. D. (1995). A familial Alzheimer's disease locus on chromosome I. Science 269:970-977.
41. MA, J., BREWER, B., and POTTER, H. (1995). Promotion of the neurotoxicity of Alzheimer's A beta protein by the pathological chaperones ACT and apoE4: inhibition by A beta-related peptides and apoE2. Soc. Neurosci. Abstr. 21:1714.
42. MA, J., YEE, A., BREWER, H. B., DAS, S. Jr., and POTTER, H. (1994). Amyloid-associated protein alpha 1-anti-chymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372:92-94.
43. MANN, D. M., PICKERING-BROWN, S. M., SIDDONS, M. A., IWATSUBO, T., IHARA, Y., ASAMI-ODAKA, A., and SUZUKI, N. (1995). The extent of amyloid deposition in brain inpatients with Down's syndrome does not depend upon apolipoprotein E genotype. Neurosci. Lett. 196:105-108.
44. MASLIAH, E., MALLORY, M., ALFORD, N., GE, M., VEINBERGS, I., and ROSES, A. D. (1995). Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Neurol. 136:107-122.
45. MASUO, Y., MATSUMOTO, Y., TOKITO, F., TSUDA, M., and FUJINO, M. (1993). Effects of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) on the spontaneous release of acetylcholine from the rat hippocampus by brain microdialysis. Brain Res. 611:207-215.
46. ++ homeostasis in Alzheimer's disease. Trends Neurosci. 16:409-414.
47. MORRIS, R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11:47-60.
48. MULLER, J. M., LELIEVRE, V., BECQ-GIRAUDON, L., and MEUNIER, A. C. (1995) VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment. Mol. Neurobiol. 10:115-134.
49. O'NEILL, C., WIEHAGER, B., FOWLER, C. J., RAVID, R., WINBLAD, B., and COWBURN, R. F. (1994). Regionally selective alterations in G protein subunit levels in the Alzheimer's disease brain. Brain Res. 636:193-201.
50. PERICAK-VANCE, M. A., and HAINES, J. L. (1995). Genetic susceptibility to Alzheimer's disease. Trends Genet. 11:504-508.
51. PINCUS, D. W., DICICCO-BLOOM, E., and BLACK, I. B. (1994). Trophic mechanisms regulate mitotic neuronal precursors: role of vasoactive intestinal peptide (VIP). Brain Res. 663:51-60.
52. PINCUS, D. W., DICICCO-BLOOM, E. M., and BLACK, I. B. (1990). Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 343:564-567.
53. PLUMP, A. S., SMITH, J. D., HAYEK, T., AALTO-SETALA, K., WALSH, A., VERSTUYFT, J. G., RUBIN, E. M., and BRESSLOW, J. L. (1992). Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353.
54. POIRIER, J. (1994). Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trend Neurosci. 17:525-530.
55. RAJAN, P., STEWART, C. L., and FINK, J. S. (1995). LIF-mediated activation of STAT proteins after neuronal injury in vivo. Neuroreport 6:2240-2244.
56. RAJAN, P., SYMES, A. J., and FINK, J. S. (1996). STAT proteins are activated by ciliary neurotrophic factor in cells of central nervous system origin. J. Neurosci. Res. 43:403-411.
57. RAO, M. S., TYRRELL, S., LANDIS, S. C., and PATTERSON, P. H. (1992). Effects of cilliary neurotrophic factor (CNTF) and depolarization on neuropeptide expression in cultured sympathetic neurons. Dev. Biol. 150:281-293.
58. ROSES, A. D., EINSTEIN, G., GILBERT, J., GOEDERT, M., HAN, S. H., HULETTE, C., MASLIAH, E., PERICAK-VANCE, M. A., SAUNDERS, A. M., SCHMECHEL, D. E., STRITTMATTER, W. J., WEISENGRABER, K. H., and XI, P. T. (1996). Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Ann. NY Acad. Sci. 777:146-157.
59. ROYSTON, M. C., MANN, D., PICKERING-BROWN, S., OWEN, F., PERRY, R., RAGHAVEN, R., KHIN-NU, C., TYRER, S., DAY, K., and CROOK, R. (1994). Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia. Neuroreport 5:2583-2585.
60. SAID, S. I. (1996). Molecules that protect: the defense of neurons and other cells. J. Clin. Invest. 97:2163-2164.
61. SAID, S. I., and MUTT, V. (1970). Polypeptide with broad biological activity: isolation from small intestine. Science 169:1217-1218.
62. SCHAAD, N. C., VANECEK, J., RODRIGUEZ, I. R., KLEIN, D. C., HOLTZCLAW, L., and RUSSELL, J. T. (1995). Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: evidence for involvement of a cyclic GMP-dependent mechanism. Mol. Pharmacol. 47:923-933.
63. SCHMECHEL, D. E., SAUNDERS, A. M., STRITTMATTER, W. J., CRAIN, B. J., HULETTE, C. M., JOO, S. H., PERICAK-VANCE, M. A., GOLDGABER, D., and ROSES, A. D. (1993). Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 15:9649-9653.
64. SELKOE, D. J. (1993). Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trend Neurosci. 16:403-409.
65. SESSLER, F. M., GRADY, S. M., WATERHOUSE, B. D., and MOISES, H. C. (1991). Electrophysiological actions of VIP in rat somatosensory cortex. Peptides 12:715-721.
66. SHAPIRA, J. (1994). Research trends in Alzheimer's disease. J. Gerontol. Nurs. 20:4-9.
67. SHERRINGTON, R., ROGAEV, E. I., LIANG, Y., ROGAEVA, E. A., LEVESQUE, G., IKEDA, M., CHI, H., LIN, C., LI, G., HOLMAN, K., TSUDA, T., MAR, L., FONCIN, J.-F., BRUNI, A. C., MONTESI, M. P., SORBI, S., RAINERO, I., PINESSI, L., NEE, L., CHUMAKOV, I., POLLEN, D., BROOKES, A., SANSEAU, P., POLLINSKY, R. J., WASCO, W., DA SILVA, H. A. R., HAINES, J. L., PERICAK-VANCE, M. A., TANZI, R. E., ROSES, A. D., FRAZER, P. E., ROMMENS, J. M., and GEORGE-HYSLOP, P. H. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754-760.
68. STRITTMATTER, W. J., and ROSES, A. D. (1995). Apolipoprotein E and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 92:4725-4727.
69. SUN, Y., RAO, M. S., ZIGMOND, R. E., and LANDIS, S. C. (1994). Regulation of vasoactive intestinal peptide expression in sympathetic neurons in culture and after axotomy: the role of cholinergic differentiation factor/ leukemia inhibitory factor. J. Neurobiol. 25:415-430.
70. SUN, Y., LANDIS, S. C., and ZIGMOND, R. E. (1996). Signals triggering the induction of leukemia inhibitory factor in sympathetic superior cervical ganglia and their nerve trunks after axonal injury. Mol Cell Neurosci. 7:152-163.
71. TANAKA, S., and KOIKE, T.(1994). Vasoactive intestinal peptide suppresses neuronal cell death induced by nerve growth factor deprivation in rat sympathetic ganglion cells in vitro. Neuropeptides 26:103-111.
72. VERGE, V. M., RICHARDSON, P. M., WIESENFELD-HALLIN, Z., and HOKFELT, T. (1995). Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J. Neurosci. 15:2081-2096.
73. WASCHEK, J. A. (1995). Vasoactive intestinal peptide: an important trophic factor and developmental regulator. Dev. Neurosci. 17:1-7.
74. WEISGRABER, K. H., PITAS, R. E., and MAHLEY, R. W. (1994). Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E. Curr. Opin. Struct. Biol. 4:507-515.
75. YAMAGUCHI, Y., and KOBAYASHI, H. (1994). Effects of vasoactive intestinal peptide (VIP) on scopolamine-induced amnesia in the rat. Neuropeptides 26:153-158.
76. ZHOU, J. N., HOFMAN, M. A., and SWAAB, D. F. (1995). VIP neurons in the human SCN in relation sex, age, and Alzheimer's disease. Neurobiol. Aging 16:571-576.